For an uncommon disease, amyotrophic lateral sclerosis (ALS) is the object of disproportionate attention these days. Synonyms include Lou Gehrig's disease, Charcot disease, and motor neuron disease. ALS is a research focus partly because it shares features with two more common public health problems-Alzheimer disease and Parkinson disease. All three affect the aging nervous system. All three are cruelly disabling and ultimately fatal. No therapy has stemmed the progression of any of them, and ALS advances most rapidly. All three are marked histologically by degeneration of specific sets of neurons and the changes are not denoted by any indication of chronic ischemia, inflammation, or vascular inadequacy. In all three, the neuronal degeneration is unexplained. Although the clinical manifestations differ, excitotoxicity and peroxidation have been implicated in theories of pathogenesis for all of them. In all three diseases, fewer than 10% of cases are familial, usually in an autosomal dominant pattern. Sometimes two of the three disorders occur in the same family or even the same person (1, 2) . Dementia is encountered ultimately in about 25% of people with Parkinson disease, often enough to be considered an integral manifestation of the condition. ALS and dementia are also paired with disproportionate frequency (1) .
ALS has proved to be a fertile field of research that covers a broad reach of modern neuroscience, drawing upon nerve growth factors, excitotoxicity (especially glutamate toxicity), free radical neurotoxicology, aberrant neuronal accumulation of neurofilaments, autoimmunity, paraneoplastic syndromes, persistent viral infection, molecular genetics, and transgenic mice (3) . Even though the disease is still irreversible, these theories have led to therapeutic trials that sustain hope for patients and their families.
A new chapter started in 1991, when a multiinstitutional team led by neurologists Tippu Siddique and Robert Brown mapped familial ALS to chromosome 21 (4) . After a few false starts, the gene product was identified as the copper/zinc superoxide dismutase type 1 (SOD1) (5 (14) .
Although new mutations must occur, remarkably few have been identified in people with the sporadic disease (17) and the SOD mutation does not account for the unusually high prevalence of the disease in Guam (18) .
The association with SOD1 makes it possible, for the first time, to generate credible theories of the pathogenesis of familial ALS. The enzyme catalyzes the dismutation of superoxide, the cytoplasmic free radical generated in normal oxidative reactions. The products are hydrogen peroxide (H202) and oxygen. If SOD were inactive, the superoxide radical would accumulate and might itself be cytotoxic because it can act as either an oxidant or a reductant (19) . Superoxide can also react with nitric oxide to form peroxynitrite (20) , which nitrates tyrosine residues to form a nitronium-like intermediate and might, thereby, interfere with the functions of SOD or other proteins.
The amino acid sequence of SOD is known and crystallographic studies have formulated a precise picture of the normal structure. Inactivation of the enzyme could result from mutations that affect either the active site or the process of dimerization. Although the known mutations do not affect the active site, the conformation or stability might be altered. If the mutant enzyme were totally inactive, residual activity should be about 50% of normal because only one allele is abnormal in a dominant disease; a loss of that magnitude might double the concentration of superoxide. In the first studies, enzyme activity was actually about 50% of normal in circulating erythrocytes (21, 22) , lymphoblastoid cell lines (23), cerebrospinal fluid of patients with familial ALS (24, 25) , and the frontal cortex of deceased patients with the disease (21). Erythrocyte SOD activity was decreased in patients with any of six mutations (20) .
As a consequence of the low SOD1 activity, the consensus viewed peroxidation and free radical damage as the agent of cytotoxicity. This theory of pathogenesis was reinforced when it was found that, in contrast to the familial form, SOD1 activity was normal in sporadic ALS by the same assays (21, 26 (27, 28 Because the disease was expressed in only one line of mice, Gurney et al. (30) stated that they could not exclude the possibility that the "site of integration of the transgene caused the disease syndrome." That possibility was excluded when other familial ALS human mutations were introduced into other strains of mice, still reproducing the motor neuron disease (31, 32) .
Ripps et al. (6) have now supplemented Gurney's observations by inducing a different SOD mutation in a different strain of mice. By using site-directed mutagenesis, they introduced a missense mutation at position 86 of the mouse SOD1 gene, changing Gly to Arg. The mutation corresponded to a human mutation at codon 85 (5, 21) . The resulting neurological disease, in two strains of mice, was accompanied by pathological changes in motor neurons of the spinal cord, brain stem, and cortex. SOD enzyme activity was normal in all tissues studied, with high expression in the central nervous system. Therefore, the disease cannot be due to the loss of an activity but is the gain of a function, a "dominant-negative" effect.
The mutant gene may encode an enzyme with low activity but expression does not alter total activity in these mice in the presence of two normal mouse alleles. The altered enzyme might, instead, impede function of the structurally normal mouse enzyme to permit accumulation of free radicals, but Bowling et al. (23) did not find evidence of free radical damage in their studies of human brain. Therefore, other possibilities must be considered. As in the transgenic mice of Ripps et al. (6) , some human mutations do not lead to loss of enzymatic activity (7, 12, 31) . Instead, a novel gain-of-function effect could alter structure of the protein that would allow access to the active site of a substrate that does not normally interact with SOD1 and result in the production and accumulation of a new and toxic species of oxygen. Alternatively, the mutation might affect the binding of copper and that cation, in local excess, might have toxic consequences. There may be more than one mechanism or a combination of mechanisms, some causing peroxidation but others having nothing to do with free radicals.
It has also been suggested (33) that overexpression of SOD in Gurney's animals could have inhibited enzyme function. However, as Gurney (34) responded, there is a clear association of the mouse disease with mutant SOD, rather than with total SOD activity, in all of the transgenic animals studied. Moreover, in mice transgenic for SOD1 and more than 2-fold overexpression of normal mouse SOD activity, paralytic disease has not been seen in adult animals (35, 36) .
Borchelt et al. (37) investigated the possibility that dimerization of the mutant and normal SOD might alter the activity, stability, or cellular localization of the normal SOD subunits. In transgenic mice, either of two mutant human SOD1 enzymes showed a shortened half-life and reduced capacity to scavenge free radicals, but the normal mouse or normal human SOD subunits were unaffected in enzyme activity or half-life. They concluded that there must be an acquisition of injurious properties by the mutant enzyme.
Whatever the mechanism, SOD is widely distributed in diverse organs, and it is not clear why motor neurons are so selectively vulnerable in either the human disease or the transgenic mouse disease. Pardo et al. (38) found immunocytochemical evidence of SOD in mouse motor neurons and in other central nervous system cells that are not affected in ALS; they concluded that "high, rather than limiting levels of SOD1 may place motor neurons selectively at risk" in familial ALS.
On the other hand, Rothstein et al. (39) found that apoptotic death of cultured spinal neurons was induced by inhibition of SOD activity. Troy and Shelanski (40) found that down-regulation of SOD induced apoptotic cell death in another neuronal cell line. But apoptosis is not characteristic of the pathology of human ALS (41); instead, ubiquinated neuronal inclusions (42) and accumulation of neurofilaments in proximal axonal swellings (43) are more commonly seen. Transgenic animals may prove important in analyzing the role of neurofilaments because overexpression of the mouse genes for neurofilament proteins leads to degeneration of motor neurons, accumulation of neurofilaments, and a paralytic disease (44) (45) (46) (47) No spontaneous animal model of ALS is completely analogous to the human disease (27) , so we can expect increasing attention to transgenic animals. It would be a tremendous boon if transgenic mice provide the vehicle for the discovery of an effective therapy (8) . The transgenic mice have already had a cautionary effect; if the mouse disease results from a toxic gainof-function effect, it may be necessary to reconsider plans already in motion to administer SOD as a treatment (51) . There is much yet to be done; we still do not know the gene products involved in 90% of families with ALS and we still have no clear clue to the pathogenesis of sporadic ALS. Nevertheless, the pace of progress is accelerating; 91% of the references for this review appeared in 1993 or later, 62% in 1994. At this rate, the scientific and human goals of ALS seem attainable.
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